NeuroSense Therapeutics Ltd.
NASDAQ Capital MarketTotal Valuation
NeuroSense Therapeutics Ltd. carries a market capitalization of 1.81M, placing it among publicly traded companies globally. Its enterprise value stands at -3.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.81M |
| Enterprise Value | -3.30M |
Share Statistics
NeuroSense Therapeutics Ltd. currently has 23.23M shares outstanding.
| Shares Outstanding | 23.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
NeuroSense Therapeutics Ltd. maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.83, indicating elevated leverage, while an interest coverage ratio of -41.78 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.21 |
| Quick Ratio | 1.78 |
| Debt / Equity | 2.83 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -41.78 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -263.14 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NeuroSense Therapeutics Ltd.'s stock has declined approximately -89.05807% over the past 52 weeks. The 50-day moving average sits at 0.17, while the 200-day moving average is 0.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.05807% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.33 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.90M, while operating income came in at -9.90M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.90M |
| Pretax Income | -10.21M |
| Net Income | -10.21M |
| EBITDA | -9.90M |
| EBIT | -9.90M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
NeuroSense Therapeutics Ltd. holds 3.38M in cash and equivalents against 73,000.00 in total debt, resulting in a net debt position of -3.38M. Total book value stands at -36.66M, with working capital of 2.41M providing operational flexibility.
| Cash & Cash Equivalents | 3.38M |
| Total Debt | 73,000.00 |
| Net Debt | -3.38M |
| Equity (Book Value) | -36.66M |
| Book Value Per Share | N/A |
| Working Capital | 2.41M |
Scores
NeuroSense Therapeutics Ltd. posts an Altman Z-Score of -17.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.73 |